Vir Biotechnology (VIR) Stock Forecast & Price Target

Vir Biotechnology is viewed favorably because its Phase 3 ECLIPSE 1 data validated a differentiated HDV strategy, with 44.1% of patients reaching the stringent composite endpoint and 79.2% achieving HDV RNA target not detected at Week 48, while safety remained clean with no SAEs or discontinuations. The combination of elebsiran and tobevibart also shows potential for finite therapy, as selected patients maintained suppression after stopping treatment, reinforcing a possible best-in-disease profile against current and emerging competitors. Beyond HDV, the company’s licensing and grant-based revenue today is supplemented by multiple oncology assets, including VIR-5500, VIR-5818, and PRO-XTEN programs, plus partnerships that may add future milestones and royalties.

Vir Biotechnology is facing a negative fundamental backdrop because its clinical-stage pipeline remains exposed to high development risk, including potential failure to demonstrate safety and efficacy in trials. The FDA-driven change request for VIR-5818 backfilling the monotherapy arm delays data release, while the ongoing combination escalation still leaves key dose and schedule questions unresolved. Commercially, the company lacks meaningful product revenue and relies mainly on license rights and grants, while long development timelines, heavy capital needs, and strong competition in HDV and TCE therapeutics raise further financing and differentiation risk.